LogicBio Therapeutics (LOGC) to Release Earnings on Wednesday

LogicBio Therapeutics (OTCMKTS:LOGC) will likely be issuing its Q1 2026 resultson Wednesday, May 13th. Analysts expect LogicBio Therapeutics to post earnings of ($0.0409) per share for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 5:00 PM ET.

LogicBio Therapeutics Trading Down 0.1%

LOGC stock opened at $8.60 on Wednesday. LogicBio Therapeutics has a 12-month low of $6.40 and a 12-month high of $9.14. The stock has a market cap of $392.76 million, a price-to-earnings ratio of -7.89 and a beta of 2.10. The business’s 50-day moving average is $8.24 and its 200 day moving average is $7.89.

Institutional Inflows and Outflows

An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. boosted its holdings in shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) by 284.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 526,673 shares of the company’s stock after acquiring an additional 389,843 shares during the quarter. Goldman Sachs Group Inc. owned about 2.00% of LogicBio Therapeutics worth $3,676,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered LogicBio Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.